A proposed amendment in Mexican law needs to be implemented urgently in order to adapt legislation to include provisions in accordance with the UPOV Convention, as Luz Flores of Uhthoff, Gómez Vega & Uhthoff reports.
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Costa Rica has released new rules for the clinical investigation of adult stem cells, as María del Pilar López and Esteban Monge of Zürcher Lawyers report.
Patenting antibodies across different jurisdictions can be a difficult task, as Kathy Coulter, senior IP counsel at Bristol-Myers Squibb, tells LSIPR.
While personalised medicine is a challenging area for drug developers, there are a number of potential solutions, as LSIPR finds out.
American biotech 3Scan is combining robotics with machine learning and automation to offer microscopy services for the 3D analysis of cells, tissues, and organs. LSIPR met general counsel Nada Rastad to hear about some of the patenting challenges.
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
Lino Almazan-Monroy and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril discuss how inventors seeking patents for polymorphs in Mexico can give themselves the best chance of success.
A well-functioning linkage system for patents and drugs allows healthcare and patent authorities to maximise the impact of innovation, say Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril, who report on the Mexican landscape.
Stephen Knight was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.